Prepare an environmental assessment or categorical-exclusion claim

How do you choose between an environmental assessment and a categorical-exclusion claim?

Identify the requested FDA action and the specific exclusion whose conditions it meets. Support those conditions and separately assess extraordinary circumstances. If no applicable exclusion is supported, prepare an environmental assessment using traceable exposure, fate and effects evidence. A low estimated concentration, natural origin or earlier IND exclusion does not establish every condition for a marketing application.

Before you begin

Human-drug and biologic environmental submissions; the appropriate analysis depends on the application action and product.

What you will prepare: An evidence-backed exclusion claim or a structured EA package for specialist review.

Classify the action, not simply the molecule

Record what FDA action is requested: IND, initial marketing application, supplement or another action. Identify active moiety, proposed use, anticipated change in use and relevant environmental characteristics. Decide whether an applicable categorical exclusion can be supported or an EA is needed.

A categorical exclusion is not a claim that the product has no conceivable environmental effect. Under 25.15, the claim identifies the particular exclusion and addresses the applicant's knowledge of extraordinary circumstances. The ordinary IND exclusion and marketing-application exclusions have different predicates. Missing forecast or environmental information leaves the determination unresolved.

Support the selected exclusion without overextending it

Collect the factual basis for the selected category. For a no-increase-in-use position, explain the market/use assumptions. For a concentration-based argument, retain the inputs, units, model and calculations. The 25.31(b) below-one-part-per-billion category does not automatically apply to BLAs; FDA's 1998 guidance explicitly distinguishes that scope.

Assess extraordinary circumstances independently. Estrogenic, androgenic or thyroid activity warrants the considerations in FDA's 2016 Q&A rather than a categorical statement that a low predicted concentration resolves every concern. Do not sign a no-extraordinary-circumstances statement on behalf of a team whose review is unfinished.

If an EA is needed, write a traceable environmental argument

Use the guidance's content structure to identify the proposed action, substance, use/disposal, environmental introductions, fate and effects evidence, evaluation and any mitigation or alternatives pertinent to the assessment. Obtain methods and reports from the environmental specialist; summarize their assumptions and uncertainty in the narrative. Separate confidential supporting material from the appropriate public-facing assessment using the applicable FDA approach.

An editorial review table can connect each exposure/effects conclusion to its source, test method, unit, relevance and uncertainty. Recalculate unit conversions independently and compare product-use projections with the commercial assumptions used elsewhere. Do not call the sponsor's conclusion an FDA finding of no significant impact.

Worked review: the action changes from IND to marketing

Fictional editorial exercise: a marketing application reuses the IND exclusion letter unchanged. The molecule has not changed, but the requested agency action has. Reassess the applicable category and supporting facts.

If a BLA draft invokes the concentration-based category solely because an NDA example did, stop and establish a legally applicable basis. If the expected use is unknown, the writer can assemble substance information but cannot complete an unsupported environmental conclusion.

Make the exclusion decision and its inputs reproducible

Use an action-specific decision record. The environmental specialist supplies the scientific assessment; the writer makes the basis, evidence and remaining uncertainty clear enough to review.

For a concentration calculation, retain the source and date for every input, its units and the reason it fits the application. FDA's July 1998 guidance describes the highest annual quantity expected for direct human use in any of the next five years, including the relevant strengths, dosage forms and related applications. It distinguishes that quantity from inventory buildup and expresses concentration as active moiety. Reconcile salt or complex mass before using it as active-moiety mass.

The historical guidance's aquatic-introduction equation can be expressed as annual active-moiety mass × unit conversion ÷ annual wastewater volume. Its printed wastewater-flow value comes from a dated survey. Do not present that value as a newly measured current national flow; document the basis for the selected input and any alternative calculation, including geographically concentrated use.

Fictional calculation exercise: assume 36,500 kg/year of active moiety and an illustrative wastewater flow of 100 billion L/day, with the guidance's simple no-metabolism assumptions. The calculation is 36,500 × 1,000,000,000 ÷ (365 × 100,000,000,000) = 1 microgram/L, or 1 ppb. These are invented inputs for checking units, not a current exposure estimate. Section 25.31(b) says below 1 ppb: exactly 1 ppb does not satisfy that numerical condition. Do not round an estimate down to claim the exclusion. Another legally applicable basis or an EA needs its own assessment.

A value below 1 ppb still does not settle extraordinary circumstances. The March 2016 guidance discusses estrogenic, androgenic and thyroid activity, including drugs that interact with those pathways without being hormones themselves. Review the total relevant evidence and explain why expected exposure would or would not create an environmental concern. A database search returning no studies is not proof of no activity.

If an EA is needed, organize the narrative around the requested action, substance and use; introductions to the environment; fate and effects evidence; evaluation of exposure against effects; uncertainty; and relevant mitigation or alternatives. Link each conclusion to its supporting method and report. Separate confidential supporting material appropriately, and keep the sponsor's proposed conclusion distinct from FDA's eventual finding of no significant impact.

Reconcile the substance identity with the drug-substance information and the action with the submission cover letter. Reopen the decision when the indication, dose, duration, expected use or requested agency action changes.

Frequently asked questions

Sources and revisions

Requirements, source recommendations and editorial preparation advice have different roles. Review the scope and revision of the source you use.

Related guides